Phase 1/2 study evaluating the safety and anti-tumor activity of PD 0332991 in combination with Velcade and dexamethasone in patients with multiple myeloma

Registry ID

EUCTR2010-022515-20

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Pfizer Inc. 235 East 42nd Street, New York, NY 10017, USA

Start date

2011-02-22

Completion date

2013-06-06

Last update

2026-08-16

Conditions

• Refractory Multiple Myeloma

Summary

Phase I  To determine the maximum tolerated dose (MTD) and RP2D of PD 0332991 in combination with bortezomib and dexamethasone Phase II  To evaluate the anti-tumor activity of PD 0332991 in combination with bortezomib and dexamethasone based on ORR as defined by IMWGURC 9

Locations

• , , Czechia
• , , Germany

Related clinical trials

• Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
• SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
• Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
• Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
• Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
• Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

View on source registry